Claim Missing Document
Check
Articles

Found 4 Documents
Search

Telmisartan Prevents Myocardial Fibrosis via Decreasing Fraction of Colagen Type 1 Volume in Myocardial Tissue in Wistar Rats-Induced High Salt Intake Radiyati Umi Partan; Rachmat Hidayat; Mgs Irsan Saleh; Nita Parisa; Evi Lusiana; Nia Savitri Tamzil; Ayeshah Augusta Rosdah; Muhammad Reagen
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 1 No. 1 (2017): Bioscientia Medicina: Journal of Biomedicine and Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v1i1.6

Abstract

Myocardial fibrosis is a pathological condition that responsible for initiation of heart failure. Neurohormonal endogen, angiotensin II, has a potential role to activate endothelin I, TGF-β1, myocardial fibroblast, extracelullar matrix deposition, structural changes and decreasing of cardiac function. Fibrotic process is also influenced by PPAR γ. Telmisartan has a potential effect to inactivate angiotensinergic system and to activate PPAR γ. It is expected that telmisartan has optimal effect to protect myocardial fibrosis. To know the role of variation dose of telmisartan to decrease collagen type 1 fraction volume in cardiac tissue of Wistar rats. Ten-week-old male Wistar Rat (n = 30) were randomized into five groups, and each group consisted of 6 rats. Group 1 : negative control. Group 2 : rats were induced by intake Nacl 8% doses 2% body weight for eight weeks. Group 3 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 3 mg/kgBB for eight weeks. Group 4 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 6 mg/kgBB for eight weeks. Group 5 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 12 mg/kgBB for eight weeks. Collagen volume fraction was assessed by immunohistochemistry and ImageJ program. ANOVA test followed pos hoc test was used to analyzed each variable. Collagen volume fraction significantly decreased in group 3, 4 and 5 compared in group 2. Telmisartan decreases collagen type 1 volume fraction of myocardial tissue .
Telmisartan Prevents Myocardial Fibrosis via Decreasing Fraction of Colagen Type 1 Volume in Myocardial Tissue in Wistar Rats-Induced High Salt Intake Radiyati Umi Partan; Rachmat Hidayat; Mgs Irsan Saleh; Nita Parisa; Evi Lusiana; Nia Savitri Tamzil; Ayeshah Augusta Rosdah; Muhammad Reagen
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 1 No. 1 (2017): Bioscientia Medicina: Journal of Biomedicine and Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v1i1.6

Abstract

Myocardial fibrosis is a pathological condition that responsible for initiation of heart failure. Neurohormonal endogen, angiotensin II, has a potential role to activate endothelin I, TGF-β1, myocardial fibroblast, extracelullar matrix deposition, structural changes and decreasing of cardiac function. Fibrotic process is also influenced by PPAR γ. Telmisartan has a potential effect to inactivate angiotensinergic system and to activate PPAR γ. It is expected that telmisartan has optimal effect to protect myocardial fibrosis. To know the role of variation dose of telmisartan to decrease collagen type 1 fraction volume in cardiac tissue of Wistar rats. Ten-week-old male Wistar Rat (n = 30) were randomized into five groups, and each group consisted of 6 rats. Group 1 : negative control. Group 2 : rats were induced by intake Nacl 8% doses 2% body weight for eight weeks. Group 3 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 3 mg/kgBB for eight weeks. Group 4 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 6 mg/kgBB for eight weeks. Group 5 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 12 mg/kgBB for eight weeks. Collagen volume fraction was assessed by immunohistochemistry and ImageJ program. ANOVA test followed pos hoc test was used to analyzed each variable. Collagen volume fraction significantly decreased in group 3, 4 and 5 compared in group 2. Telmisartan decreases collagen type 1 volume fraction of myocardial tissue .
Chondroprotective Potential of Oleocanthal and Hydroxytyrosol from Extra Virgin Olive Oil: A Meta-Analysis Muhammad Addien Prima Nanda; Muhammad Reagen
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1276

Abstract

Background: Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by cartilage degradation, inflammation, and pain. Oleocanthal and hydroxytyrosol, two potent anti-inflammatory and antioxidant polyphenols found in extra virgin olive oil (EVOO), have shown promising chondroprotective effects in preclinical studies. This meta-analysis aimed to evaluate the efficacy of oleocanthal and hydroxytyrosol in preventing cartilage degradation and ameliorating OA symptoms. Methods: A systematic search of electronic databases (PubMed, Scopus, and Web of Science) was conducted to identify relevant studies published between 2013 and 2024. Randomized controlled trials (RCTs) and preclinical studies investigating the effects of oleocanthal or hydroxytyrosol on OA were included. The primary outcome was cartilage degradation, assessed by imaging or histological scores. Secondary outcomes included pain and inflammation. Results: Nine studies (4 RCTs and 5 preclinical studies) met the inclusion criteria. The RCTs included a total of 315 participants with knee OA. The interventions consisted of oral administration of oleocanthal or hydroxytyrosol at various doses and durations. The preclinical studies used different in vivo animal models. Pooled analysis of the RCTs showed that oleocanthal or hydroxytyrosol significantly reduced cartilage degradation compared to control (SMD = -0.85, 95%CI -1.20 to -0.50, p < 0.001). In the preclinical studies, oleocanthal and hydroxytyrosol also significantly reduced cartilage degradation scores (SMD = -1.10, 95%CI -1.50 to -0.70, p < 0.001). Pooled analysis of pain outcomes showed a significant reduction with oleocanthal or hydroxytyrosol compared to control (Preclinical: SMD = -0.60, 95%CI -0.90 to -0.30, p < 0.001; RCTs: SMD=-1.20, 95%CI-1.60 to -0.80, p < 0.001). Oleocanthal and hydroxytyrosol significantly reduced inflammatory markers (Preclinical: SMD = -0.85, 95%CI-1.15 to -0.55, p < 0.001; RCTs: SMD= -1.50, 95%CI-1.90 to -1.10, p < 0.001). Conclusion: This meta-analysis provides evidence for the chondroprotective potential of oleocanthal and hydroxytyrosol from EVOO. These polyphenols may offer a promising therapeutic strategy for preventing cartilage degradation, reducing pain, and improving OA symptoms. Further large-scale RCTs are warranted to confirm these findings and establish optimal dosage and treatment duration.
Chondroprotective Potential of Oleocanthal and Hydroxytyrosol from Extra Virgin Olive Oil: A Meta-Analysis Muhammad Addien Prima Nanda; Muhammad Reagen
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1276

Abstract

Background: Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by cartilage degradation, inflammation, and pain. Oleocanthal and hydroxytyrosol, two potent anti-inflammatory and antioxidant polyphenols found in extra virgin olive oil (EVOO), have shown promising chondroprotective effects in preclinical studies. This meta-analysis aimed to evaluate the efficacy of oleocanthal and hydroxytyrosol in preventing cartilage degradation and ameliorating OA symptoms. Methods: A systematic search of electronic databases (PubMed, Scopus, and Web of Science) was conducted to identify relevant studies published between 2013 and 2024. Randomized controlled trials (RCTs) and preclinical studies investigating the effects of oleocanthal or hydroxytyrosol on OA were included. The primary outcome was cartilage degradation, assessed by imaging or histological scores. Secondary outcomes included pain and inflammation. Results: Nine studies (4 RCTs and 5 preclinical studies) met the inclusion criteria. The RCTs included a total of 315 participants with knee OA. The interventions consisted of oral administration of oleocanthal or hydroxytyrosol at various doses and durations. The preclinical studies used different in vivo animal models. Pooled analysis of the RCTs showed that oleocanthal or hydroxytyrosol significantly reduced cartilage degradation compared to control (SMD = -0.85, 95%CI -1.20 to -0.50, p < 0.001). In the preclinical studies, oleocanthal and hydroxytyrosol also significantly reduced cartilage degradation scores (SMD = -1.10, 95%CI -1.50 to -0.70, p < 0.001). Pooled analysis of pain outcomes showed a significant reduction with oleocanthal or hydroxytyrosol compared to control (Preclinical: SMD = -0.60, 95%CI -0.90 to -0.30, p < 0.001; RCTs: SMD=-1.20, 95%CI-1.60 to -0.80, p < 0.001). Oleocanthal and hydroxytyrosol significantly reduced inflammatory markers (Preclinical: SMD = -0.85, 95%CI-1.15 to -0.55, p < 0.001; RCTs: SMD= -1.50, 95%CI-1.90 to -1.10, p < 0.001). Conclusion: This meta-analysis provides evidence for the chondroprotective potential of oleocanthal and hydroxytyrosol from EVOO. These polyphenols may offer a promising therapeutic strategy for preventing cartilage degradation, reducing pain, and improving OA symptoms. Further large-scale RCTs are warranted to confirm these findings and establish optimal dosage and treatment duration.